Salus Discovery

Executive Summary

Salus Discovery, founded in 2019 and headquartered in San Diego, is a private molecular diagnostics company that integrates AI, machine learning, microfluidics, and biochemistry to develop novel diagnostic solutions for cancer and infectious diseases. The company's multidisciplinary approach combines physics, engineering, and informatics to address longstanding challenges in diagnostics, aiming to create simple yet impactful tools. Despite limited public information on funding or valuation, Salus Discovery’s profile on BiopharmGuy suggests it is an early-stage entity with potential for growth. The company’s focus on unifying diverse scientific domains positions it to deliver innovative point-of-care or lab-based diagnostic platforms that could improve detection speed, accuracy, and accessibility. However, the lack of disclosed milestones or commercial products indicates a need for further validation and capital to advance its pipeline. As a private firm with no reported revenue or FDA approvals, Salus Discovery represents an early investment opportunity with high uncertainty but significant potential in the precision diagnostics space.

Upcoming Catalysts (preview)

• Q3 2026Series A or Seed Funding Announcement60% success
• Q4 2026First Diagnostic Platform Proof-of-Concept Data Release45% success
• Q2 2027Strategic Partnership or Licensing Deal with a Diagnostic Company30% success